|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Conjugate||Alexa Fluor® 700|
|Storage buffer||PBS with BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, store in dark|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Flow Cytometry (Flow)||See 1 publications below|
The Alexa Fluor® 700 dye conjugate provides an excellent spectral match to the common long-wavelength excitation sources, with a high extinction coefficient.
This gene encodes a receptor for the Fc portion of immunoglobulin G, and it is involved in the removal of antigen-antibody complexes from the circulation, as well as other other antibody-dependent responses. This gene (FCGR3A) is highly similar to another nearby gene (FCGR3B) located on chromosome 1. The receptor encoded by this gene is expressed on natural killer (NK) cells as an integral membrane glycoprotein anchored through a transmembrane peptide, whereas FCGR3B is expressed on polymorphonuclear neutrophils (PMN) where the receptor is anchored through a phosphatidylinositol (PI) linkage. Mutations in this gene have been linked to susceptibility to recurrent viral infections, susceptibility to systemic lupus erythematosus, and alloimmune neonatal neutropenia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
Analyte Specific Reagent
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.
MHCD1629 was used in flow cytometry to characterize therapy-induced T cell reactivity using a panel of 45 melanoma-associated CD8(+) T cell epitopes.
|Kvistborg P,Shu CJ,Heemskerk B,Fankhauser M,Thrue CA,Toebes M,van Rooij N,Linnemann C,van Buuren MM,Urbanus JH,Beltman JB,Thor Straten P,Li YF,Robbins PF,Besser MJ,Schachter J,Kenter GG,Dudley ME,Rosenberg SA,Haanen JB,Hadrup SR,Schumacher TN||Oncoimmunology (1:409)||2012|